Tumor-Infiltrating Lymphocytes Provide ‘Viable Option’ for Advanced Melanoma


Sumary of Tumor-Infiltrating Lymphocytes Provide ‘Viable Option’ for Advanced Melanoma:

  • Rosenberg, MD, PhD, chief of the surgery branch and head of the tumor immunology section of NCI Center for Cancer Research, published the first report on the use of tumor-infiltrating lymphocytes (TILs) for the treatment of melanoma in 1988..
  • Since then, this approach has remained relegated mostly to research facilities like the NIH and other large academic medical centers..
  • Patients with melanoma who have disease progression after receiving immune checkpoint inhibitors have few options other than clinical trials, according to Warren A..
  • Now, after 30-plus years in development, TILs soon may become commercially available for cancer treatment based on phase 1 and phase 2 trial results among patients with advanced melanoma..
  • As one of the earliest forms of cancer immunotherapy, TILs may benefit from the clinical testing and regulatory approval trail blazed by chimeric antigen receptor T-cell therapy, the first gene-edited adoptive cell therapy approved for commercial use in the United States..
  • “If approved, [TIL therapy] would be an option for approximately 10,000 [patients with] stage IV melanoma who die each year in the United States alone,”.
  • Chesney, MD, PhD, director of James Graham Brown Cancer Center and associate vice president for health affairs at University of Louisville, told Cell Therapy Next..
  • “Instead of going into hospice, receiving a palliative regimen of chemotherapy or another line of ineffective immunotherapy, this would be a viable option [from] which a significant proportion of patients would have a durable response.”…

Want to know more click here go to source.

From -
Generic selectors
Exact matches only
Search in title
Search in content

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.